VOL. XCIV, NO. 247

★ WIDE MOAT STOCKS COMPARISON ★

NO ADVICE

Thursday, January 8, 2026

Stock Comparison

Boston Scientific Corporation vs TransDigm Group Incorporated

Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.

Boston Scientific Corporation

BSX · New York Stock Exchange

Market cap (USD)$141.5B
Gross margin (TTM)65.1%
Operating margin (TTM)17.3%
Net margin (TTM)14.4%
SectorHealthcare
IndustryMedical - Devices
CountryUS
Data as of2026-01-04
Moat score
65/ 100

Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.

Full stock profile

Dive deeper into Boston Scientific Corporation's moat claims, evidence, and risks.

View BSX analysis

TransDigm Group Incorporated

TDG · New York Stock Exchange

Market cap (USD)$77B
Gross margin (TTM)60.2%
Operating margin (TTM)47.2%
Net margin (TTM)23.5%
SectorIndustrials
IndustryAerospace & Defense
CountryUS
Data as of2025-12-31
Moat score
84/ 100

Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.

Full stock profile

Dive deeper into TransDigm Group Incorporated's moat claims, evidence, and risks.

View TDG analysis

Comparison highlights

  • Moat score gap: TransDigm Group Incorporated leads (84 / 100 vs 65 / 100 for Boston Scientific Corporation).
  • Segment focus: Boston Scientific Corporation has 5 segments (49.8% in Cardiology); TransDigm Group Incorporated has 3 segments (51.6% in Power & Control).
  • Primary market structure: Oligopoly vs Competitive. Pricing power: Moderate vs Strong.
  • Moat breadth: Boston Scientific Corporation has 6 moat types across 3 domains; TransDigm Group Incorporated has 5 across 3.

Primary market context

Boston Scientific Corporation

Cardiology

Market

Cardiology devices (interventional cardiology, structural heart, electrophysiology, cardiac rhythm management and remote monitoring)

Geography

Global

Customer

Hospitals/cath labs/EP labs and specialty clinics (cardiologists, electrophysiologists)

Role

Medical device OEM / implantables + procedure devices + service-enabled monitoring

Revenue share

49.8%

TransDigm Group Incorporated

Power & Control

Market

Highly engineered aerospace power & control components (OEM and aftermarket)

Geography

Global

Customer

Commercial airlines, aircraft OEMs, defense OEMs, governments, aerospace distributors

Role

Tier 2/3 component OEM, aftermarket spares, repair/overhaul

Revenue share

51.6%

Side-by-side metrics

Boston Scientific Corporation
TransDigm Group Incorporated
Ticker / Exchange
BSX - New York Stock Exchange
TDG - New York Stock Exchange
Market cap (USD)
$141.5B
$77B
Gross margin (TTM)
65.1%
60.2%
Operating margin (TTM)
17.3%
47.2%
Net margin (TTM)
14.4%
23.5%
Sector
Healthcare
Industrials
Industry
Medical - Devices
Aerospace & Defense
HQ country
US
US
Primary segment
Cardiology
Power & Control
Market structure
Oligopoly
Competitive
Market share
n/a
n/a
HHI estimate
n/a
n/a
Pricing power
Moderate
Strong
Moat score
65 / 100
84 / 100
Moat domains
Demand, Legal, Supply
Demand, Legal, Supply
Last update
2026-01-04
2025-12-31

Moat coverage

Shared moat types

Installed Base ConsumablesRegulated Standards Pipe

Boston Scientific Corporation strengths

Procurement InertiaTraining Org Change CostsReputation ReviewsDistribution Control

TransDigm Group Incorporated strengths

Design In QualificationOperational ExcellenceSmall legacy non-aviation portfolio

Segment mix

Boston Scientific Corporation segments

Full profile >

Endoscopy

Oligopoly

16%

Urology

Competitive

13.1%

Neuromodulation

Oligopoly

6.6%

Cardiology

Oligopoly

49.8%

Peripheral Interventions

Competitive

14.4%

TransDigm Group Incorporated segments

Full profile >

Power & Control

Competitive

51.6%

Airframe

Competitive

46.6%

Non-aviation

Competitive

1.8%

Want the full wide moat stocks list?

Browse the full ranking of wide moat stocks, updated with moat scores and segment context.

View the moat stocks list

Looking for expansion-stage stocks?

Proven models entering the expansion stage with unit economics that work.

View expansion-stage stocks

Curation & Accuracy

This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).

Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.